Related Experiment Video
Updated: Apr 11, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
EGFR mutations and EGFR tyrosine kinase inhibitors
Valter Torri1, Massimo Broggini1, Marina Chiara Garassino2
1IRCCS Istituto di Ricerche Farmacologiche Mario Negri (IRFMN), Milan, Italy.
No abstract available in PubMed .
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Receptor Tyrosine Kinases
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cancer